A Clinical Phase II Trial to Describe Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Spectrila® With the Pharmaceutical Active Ingredient Recombinant L Asparaginase in Adult Subjects With Newly Diagnosed Acute B-Cell Lymphoblastic Leukaemia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Recombinant L-Asparaginase-medac (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Medac
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2018 Planned initiation date changed from 15 May 2018 to 15 Dec 2018.
- 26 Mar 2018 Planned initiation date changed from 15 Dec 2017 to 15 May 2018.